Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wilbur Chen

Infectious Disease Baltimore, MD Medical Doctor

NPI 1891758975 CMS profile 474252

22 S Greene St, Baltimore, MD 21201

Open in the dashboard

General payments

$33,078

22 records reported · program years 2019–2025

Research payments

$1,209

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$938,286 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Wilbur Chen of Baltimore, MD is reported in the CMS Open Payments database as having received $33,078 across 22 general payments and $1,209 in research payments paid to them. Separately, studies naming them as principal investigator received $938,286 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,530 3
2024 General $9,082 12
2019 General $19,466 7
2019 Research $1,209 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wilbur Chen
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Wilbur Chen were reported at $4,530. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Wilbur Chen Infectious Disease median Middle half National median
2019 $19,466 $190 $60–$862 $163
2020 $0 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $0 $166 $50–$834 $149
2023 $0 $171 $57–$787 $160
2024 $9,082 $176 $52–$752 $164
2025 $4,530 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Global Services, LLC $14,262 3 payments
  2. Sanofi Pasteur Inc. $6,376 5 payments
  3. Seqirus USA Inc $5,548 4 payments
  4. Pfizer Inc. $3,250 1 payment
  5. Merck Sharp & Dohme Corporation $2,855 8 payments
  6. Emergent BioSolutions Inc. $786 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,571 5 payments
  2. Travel and Lodging $9,277 9 payments
  3. Honoraria $3,500 1 payment
  4. Food and Beverage $1,730 7 payments
Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,209 18 payments

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record